Lentivirus News and Research

RSS

Lentivirus is a genus of slow viruses of the Retroviridae family, characterized by a long incubation period.

Virus-like particles reveal unexpected mechanism for increased fitness and spread of SARS-CoV-2

Researchers in the United States have developed a new model for testing mutations in the four structural proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

9 Aug 2021

Accelerating the design of minibinder therapeutics resilient to SARS-CoV-2 mutations

Multivalent protein-based minibinders hold great promise as potential prophylactic and treatment agents, as they can retain their activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. This was revealed in a recent tour-de-force research study currently available on the bioRxiv* preprint server while the article undergoes the peer review process.

11 Jul 2021

CRISPRa identifies potassium channels as neuronal entry factors and druggable targets for SARS-CoV-2

New research led by Le Cong of Stanford University School of Medicine in California indicates that the KCNA6 potassium channel may help with viral entry and promote infection. In addition, KCNA6 is highly expressed in OLIG2+ neuronal cells, which has been shown to be suspectable to SARS-CoV-2 in the olfactory neuroepithelium. This area appears to contribute to loss of smell commonly observed during infection.

6 Jul 2021

Study says mRNA COVID vaccines are effective against Lambda variant

Researchers in the United States have conducted a study suggesting that the coronavirus disease 2019 (COVID-19) vaccines that are currently being rolled out in many countries should be effective against the C.37 lineage (lambda variant) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Jul 2021

Is mild COVID-19 in children due to stronger antiviral innate immunity in the upper airway?

A new preprint on the medRxiv* server adds fuel to this train of thought, showing that the required cell program is already active in children – namely, a higher expression of specific pattern recognition receptors (PRRs), which mediate an interferon (IFN) response.

30 Jun 2021

New approach to gene therapy uses common pain reliever to fight against genetic diseases

Researchers have developed a new approach to gene therapy that leans on the common pain reliever acetaminophen to force a variety of genetic diseases into remission.

14 Jun 2021

Humoral innate pattern recognition molecules against SARS-CoV-2

In a paper recently uploaded to the preprint server medRxiv by Garlanda et al. (June 8th, 2021), humoral pattern recognition molecules are explored for affinity towards SARS-CoV-2, contributing to unraveling the role of these molecules in COVID-19 disease progression.

13 Jun 2021

AMSBIO's custom lentivectors for labeling organoids

AMSBIO have supplied custom lentivectors to Francesco Pampaloni and his team at the Buchmann Institute for Molecular Life Sciences in Frankfurt, Germany allowing them to visualize cell nuclei and F-actin cytoskeleton in their organoids.

From AMS Biotechnology 1 Jun 2021

Corilagin: could a plant compound used in Chinese herbal medicine help prevent COVID-19?

The study, published in the journal Phytomedicine, characterized an active compound, corilagin (a derivative from Phyllanthus urinaria), as potential SARS-CoV-2 entry inhibitors for its preventive application in daily antiviral hygiene products.

31 May 2021

Glycosylation a significant element in SARS-CoV-2 infection and vaccine design, says study

A new study by researchers from Taiwan and the US suggests that the removal of unnecessary glycans from spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposes highly conserved sequences and opens the door for the development of broadly protective vaccines against the virus and its variants.

28 May 2021

Investigational gene therapy can restore immune function in children with inherited immunodeficiency disorder

An investigational gene therapy can safely restore the immune systems of infants and children who have a rare, life-threatening inherited immunodeficiency disorder, according to research supported in part by the National Institutes of Health.

12 May 2021

Experimental gene therapy successfully treats children born without an immune system

An experimental form of gene therapy developed by a team of researchers from UCLA and Great Ormond Street Hospital in London has successfully treated 48 of 50 children born with a rare and deadly inherited disorder that leaves them without an immune system.

11 May 2021

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

A study recently published in the journal Matter has demonstrated the development and validation of a nanoparticle-based formulation, capable of completely inhibiting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection blocking the interaction between viral spike protein and host cell angiotensin-converting enzyme 2 (ACE2).

3 May 2021

SARS-CoV-2 limits type I and type III IFN protein biogenesis

New research led by Roy Parker of the University of Colorado Boulder finds that SARS-CoV-2 prevents the IFN response despite an increased presence of IFN-encoding mRNAs by suppressing transcriptional processes. Inhibition of IFN mRNAs triggers degradation from the activation of RNase L and the SARS-CoV-2 protein Nsp1.

26 Apr 2021

Can SARS-CoV-2 host factor protein interactions help identify antiviral drug targets?

In a new study proteomic peptide-phage display is utilized to profile the novel SLiM-based interactions that mediate host factor interactions in 229 RNA viruses, with a special focus on SARS-CoV-2, to reveal mechanistic insights and identify drug targets.

22 Apr 2021

Potent nanobody binds SARS-CoV-2 spike in an extraordinary manner

In a new study, published recently on the bioRxiv preprint server, researchers isolated a nanobody that potently neutralizes SARS-CoV-2, including the B.1.351 variant, and cross-neutralizes SARS-CoV. They demonstrated the therapeutic potential of the nanobody in a human ACE2 (angiotensin-converting enzyme) transgenic mouse model.

24 Mar 2021

Dandelion extract inhibits SARS-CoV-2 in vitro

An exciting new study describes a specific inhibitor of the SARS-CoV-2 found in an extract of the common dandelion that could provide a new and fruitful avenue of drug research.

23 Mar 2021

Circular RNA vaccine shows neutralizing activity against B.1.351 variant

New preclinical research led by Wensheng Wei from Peking University in China has proposed the development of a circular RNA vaccine. Their findings showed the circular RNA vaccine creates neutralizing antibodies and strong T-cell responses against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

21 Mar 2021

Canadian pilot study uses gene therapy to successfully treat patients with Fabry disease

Results of a world-first Canadian pilot study on patients treated with gene therapy for Fabry disease show that the treatment is working and safe.

25 Feb 2021

New mouse model of SARS-CoV-2 infection reflects features of human infection

Now, a new preprint research paper posted to the bioRxiv server reports the development of a modified mouse model that allows productive SARS-CoV-2 infection of the mouse lungs, as well as the exploration of type I and III interferon responses in this condition.

14 Feb 2021

Lentivirus News and Research

Further Reading

Virus-like particles reveal unexpected mechanism for increased fitness and spread of SARS-CoV-2

Accelerating the design of minibinder therapeutics resilient to SARS-CoV-2 mutations

CRISPRa identifies potassium channels as neuronal entry factors and druggable targets for SARS-CoV-2

Study says mRNA COVID vaccines are effective against Lambda variant

Is mild COVID-19 in children due to stronger antiviral innate immunity in the upper airway?

New approach to gene therapy uses common pain reliever to fight against genetic diseases

Humoral innate pattern recognition molecules against SARS-CoV-2

AMSBIO's custom lentivectors for labeling organoids

Corilagin: could a plant compound used in Chinese herbal medicine help prevent COVID-19?

Glycosylation a significant element in SARS-CoV-2 infection and vaccine design, says study

Investigational gene therapy can restore immune function in children with inherited immunodeficiency disorder

Experimental gene therapy successfully treats children born without an immune system

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

SARS-CoV-2 limits type I and type III IFN protein biogenesis

Can SARS-CoV-2 host factor protein interactions help identify antiviral drug targets?

Potent nanobody binds SARS-CoV-2 spike in an extraordinary manner

Dandelion extract inhibits SARS-CoV-2 in vitro

Circular RNA vaccine shows neutralizing activity against B.1.351 variant

Canadian pilot study uses gene therapy to successfully treat patients with Fabry disease

New mouse model of SARS-CoV-2 infection reflects features of human infection

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics